As medicine increases its focus on personalized medicine, understanding factors which can alter the pharmacokinetics, pharmacodynamics, efficacy, and safety of medications is essential. More than 100 years ago experimental toxicologists noted sex differences in response to drug and/or chemical exposures. RSI continues to study these differing response today.
Recently the FDA has drawn attention to sex differences in sleeping aids, including zolpidem and more recently, suvorexant. The effectiveness and safety of these drugs among both men and women is a major cause of concern, and RSI brings a long history analyzing and understanding the sex differences in pharmacology of drugs.